These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 10715162)

  • 41. Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists.
    Thomas JB; Mascarella SW; Rothman RB; Partilla JS; Xu H; McCullough KB; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 May; 41(11):1980-90. PubMed ID: 9599247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chiral synthesis and pharmacological evaluation of NPS 1407: a potent, stereoselective NMDA receptor antagonist.
    Moe ST; Smith DL; DelMar EG; Shimizu SM; Van Wagenen BC; Balandrin MF; Chien YE; Raszkiewicz JL; Artman LD; White HS; Mueller AL
    Bioorg Med Chem Lett; 2000 Nov; 10(21):2411-5. PubMed ID: 11078190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
    Maier CA; Wünsch B
    J Med Chem; 2002 Jan; 45(2):438-48. PubMed ID: 11784148
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization.
    Efange SM; Tu Z; von Hohenberg K; Francesconi L; Howell RC; Rampersad MV; Todaro LJ; Papke RL; Kung MP
    J Med Chem; 2001 Dec; 44(26):4704-15. PubMed ID: 11741488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
    López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
    J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes.
    Pahk AJ; Williams K
    Neurosci Lett; 1997 Mar; 225(1):29-32. PubMed ID: 9143010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterisation of N-methyl-D-aspartate receptor-specific [(3)H]Ifenprodil binding to recombinant human NR1a/NR2B receptors compared with native receptors in rodent brain membranes.
    Grimwood S; Richards P; Murray F; Harrison N; Wingrove PB; Hutson PH
    J Neurochem; 2000 Dec; 75(6):2455-63. PubMed ID: 11080197
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer.
    Roger G; Lagnel B; Besret L; Bramoullé Y; Coulon C; Ottaviani M; Kassiou M; Bottlaender M; Valette H; Dollé F
    Bioorg Med Chem; 2003 Dec; 11(24):5401-8. PubMed ID: 14642584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses.
    Chenard BL; Bordner J; Butler TW; Chambers LK; Collins MA; De Costa DL; Ducat MF; Dumont ML; Fox CB; Mena EE
    J Med Chem; 1995 Aug; 38(16):3138-45. PubMed ID: 7636876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro characterization of novel NR2B selective NMDA receptor antagonists.
    Kiss L; Cheng G; Bednar B; Bednar RA; Bennett PB; Kane SA; McIntyre CJ; McCauley JA; Koblan KS
    Neurochem Int; 2005 May; 46(6):453-64. PubMed ID: 15769547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and resolution of racemic eliprodil and evaluation of the enantiomers of eliprodil as NMDA receptor antagonists.
    Pabel J; Höfner G; Wanner KT
    Bioorg Med Chem Lett; 2000 Jun; 10(12):1377-80. PubMed ID: 10890168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist.
    Woodward RM; Huettner JE; Tran M; Guastella J; Keana JF; Weber E
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1209-18. PubMed ID: 8531083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacological characterization of interactions of RO 25-6981 with the NR2B (epsilon2) subunit.
    Lynch DR; Shim SS; Seifert KM; Kurapathi S; Mutel V; Gallagher MJ; Guttmann RP
    Eur J Pharmacol; 2001 Mar; 416(3):185-95. PubMed ID: 11290368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells.
    Priestley T; Laughton P; Myers J; Le Bourdellés B; Kerby J; Whiting PJ
    Mol Pharmacol; 1995 Nov; 48(5):841-8. PubMed ID: 7476914
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
    Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine-dicarboxylate: enhanced excitotoxic potency and selectivity.
    Willis CL; Dauenhauer DL; Humphrey JM; Chamberlin AR; Buller AL; Monaghan DT; Bridges RJ
    Toxicol Appl Pharmacol; 1997 May; 144(1):45-55. PubMed ID: 9169068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.
    Carter C; Benavides J; Legendre P; Vincent JD; Noel F; Thuret F; Lloyd KG; Arbilla S; Zivkovic B; MacKenzie ET
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1222-32. PubMed ID: 2849669
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Syntheses, activity and modeling studies of 3- and 4-(sulfo- and sulfonamidoalkyl)pyridine and piperidine-2-carboxylic acid derivatives as analogs of NMDA receptor antagonists.
    el Hadri A; Maldivi P; Leclerc G; Rocher JP
    Bioorg Med Chem; 1995 Sep; 3(9):1183-201. PubMed ID: 8564410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity.
    Jimonet P; Ribeill Y; Bohme GA; Boireau A; Chevé M; Damour D; Doble A; Genevois-Borella A; Herman F; Imperato A; Le Guern S; Manfré F; Pratt J; Randle JC; Stutzmann JM; Mignani S
    J Med Chem; 2000 Jun; 43(12):2371-81. PubMed ID: 10882363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological characterization at ionotropic glutamate receptors of compounds related to glutamate and its homologues.
    Lolli ML; Giordano C; Pickering DS; Rolando B; Hansen KB; Foti A; Contreras-Sanz A; Amir A; Fruttero R; Gasco A; Nielsen B; Johansen TN
    J Med Chem; 2010 May; 53(10):4110-8. PubMed ID: 20408529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.